OPTR Share Price

Open 12.89 Change Price %
High 13.00 1 Day -0.15 -1.16
Low 12.56 1 Week 0.00 0.00
Close 12.78 1 Month 0.00 0.00
Volume 10093864 1 Year 0.00 0.00
52 Week High 23.59
52 Week Low 0.00
OPTR Important Levels
Resistance 2 13.19
Resistance 1 13.02
Pivot 12.78
Support 1 12.54
Support 2 12.37
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR)

OPTR Technical Analysis 3
As on 23rd Oct 2013 OPTR Share Price closed @ 12.78 and we RECOMMEND Buy for LONG-TERM with Stoploss of 12.48 & Buy for SHORT-TERM with Stoploss of 12.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPTR Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
OPTR Other Details
Segment EQ
Market Capital 453062368.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
OPTR Address
OPTR
N/A
Interactive Technical Analysis Chart Optimer Pharmaceuticals, Inc. ( OPTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Optimer Pharmaceuticals, Inc.
OPTR Business Profile
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company�s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer�s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.